{"entity":{"edinet_code":"E00945","sec_code":"4528","name_ja":"小野薬品工業株式会社","name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","industry":"医薬品","industry_en":"Pharmaceutical"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100YOIE","filer_name":"小野薬品工業株式会社","filer_name_en":"ONO　PHARMACEUTICAL　CO.,　LTD.","period_end":"2026-03-31","filed_date":"2026-07-08","sha256":"4fed377347fdd7b290bc1996a6044c8416ce671cf706d56eff3fd66417e11f25","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"parent_only","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"The reporting company itself (提出会社) — the holding company, excluding the group holders it names separately.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"reporting","held_name_raw":"参天製薬（株）","held_name_en":"SANTEN PHARMACEUTICAL CO., LTD.","held_sec_code":"4536","match_status":"matched","shares":6204425,"book_value_yen":11078000000,"prior_shares":6204425,"prior_book_value_yen":8798000000,"purpose_ja":"医薬品事業において、事業上の関係を維持・強化し、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":1.9285934410418983,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.3021803704361095,"pct_of_holder_assets":1.001161303732891,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）Ｔ＆Ｄホールディングス","held_name_en":"T&D Holdings, Inc.","held_sec_code":"8795","match_status":"matched","shares":1693010,"book_value_yen":6698000000,"prior_shares":1693010,"prior_book_value_yen":5374000000,"purpose_ja":"取引先(金融機関)として、取引関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有 （注４）","pct_outstanding":0.3508287321439488,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.787326604186772,"pct_of_holder_assets":0.6053239224050284,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":["4"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"大塚ホールディングス（株）","held_name_en":"Otsuka Holdings Co., Ltd.","held_sec_code":"4578","match_status":"matched","shares":469100,"book_value_yen":5165000000,"prior_shares":469100,"prior_book_value_yen":3637000000,"purpose_ja":"医薬品事業において、事業上の関係を維持・強化し、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.08882258939729011,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.6071277859995039,"pct_of_holder_assets":0.46678083894027644,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"キッコーマン（株）","held_name_en":"KIKKOMAN CORPORATION","held_sec_code":"2801","match_status":"matched","shares":3585000,"book_value_yen":5144000000,"prior_shares":3585000,"prior_book_value_yen":5166000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.3868814657025372,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.6046593090380346,"pct_of_holder_assets":0.4648829884818552,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ダイキン工業（株）","held_name_en":"DAIKIN INDUSTRIES,LTD.","held_sec_code":"6367","match_status":"matched","shares":234800,"book_value_yen":4387000000,"prior_shares":469600,"prior_book_value_yen":7579000000,"purpose_ja":"事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.08018110466498209,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5156765919031605,"pct_of_holder_assets":0.39646999814733647,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":0.5,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ＣＫＤ（株）","held_name_en":"CKD Corporation","held_sec_code":"6407","match_status":"matched","shares":925000,"book_value_yen":3950000000,"prior_shares":925000,"prior_book_value_yen":1869000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":1.3840043717181982,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4643087618002015,"pct_of_holder_assets":0.35697663384590356,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日清食品ホールディングス（株）","held_name_en":"NISSIN FOODS HOLDINGS CO.,LTD.","held_sec_code":"2897","match_status":"matched","shares":1230000,"book_value_yen":3696000000,"prior_shares":1845000,"prior_book_value_yen":5633000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.4277601746930821,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4344519452186189,"pct_of_holder_assets":0.33402168068214166,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）島津製作所","held_name_en":"Shimadzu Corporation","held_sec_code":"7701","match_status":"matched","shares":919000,"book_value_yen":3390000000,"prior_shares":919000,"prior_book_value_yen":3428000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.31798303726234917,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3984827094943501,"pct_of_holder_assets":0.3063672882880033,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日本新薬（株）","held_name_en":"Nippon Shinyaku Co., Ltd.","held_sec_code":"4516","match_status":"matched","shares":620000,"book_value_yen":3170000000,"prior_shares":620000,"prior_book_value_yen":2357000000,"purpose_ja":"医薬品事業において、事業上の関係を維持・強化し、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.9198678761129065,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3726224746599085,"pct_of_holder_assets":0.2864850453902568,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）大阪ソーダ","held_name_en":"OSAKA SODA CO., LTD.","held_sec_code":"4046","match_status":"matched","shares":1750000,"book_value_yen":2987000000,"prior_shares":1750000,"prior_book_value_yen":2842000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":1.4244772483918364,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3511114611385321,"pct_of_holder_assets":0.2699466342525858,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）三菱ＵＦＪフィナンシャル・グループ","held_name_en":"Mitsubishi UFJ Financial Group, Inc.","held_sec_code":"8306","match_status":"matched","shares":1121980,"book_value_yen":2917000000,"prior_shares":1121980,"prior_book_value_yen":2256000000,"purpose_ja":"取引先(金融機関)として、取引関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有（注５）","pct_outstanding":0.009932236225520355,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3428832046003007,"pct_of_holder_assets":0.2636204660578483,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":["5"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）スズケン","held_name_en":"SUZUKEN CO.,LTD.","held_sec_code":"9987","match_status":"matched","shares":432058,"book_value_yen":2564000000,"prior_shares":432058,"prior_book_value_yen":2134000000,"purpose_ja":"取引先(特約店)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.6387808823880764,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3013892823432194,"pct_of_holder_assets":0.23171850359010046,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"アルフレッサホールディングス（株）","held_name_en":"Alfresa Holdings Corporation","held_sec_code":"2784","match_status":"matched","shares":948620,"book_value_yen":2398000000,"prior_shares":948620,"prior_book_value_yen":2003000000,"purpose_ja":"取引先(特約店)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有（注６）","pct_outstanding":0.5206410676484325,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2818765596954135,"pct_of_holder_assets":0.21671644758543715,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":["6"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"東邦ホールディングス（株）","held_name_en":"TOHO HOLDINGS CO.,LTD.","held_sec_code":"8129","match_status":"matched","shares":399350,"book_value_yen":1902000000,"prior_shares":399350,"prior_book_value_yen":1781000000,"purpose_ja":"取引先(特約店)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.6174314782476888,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2235734847959451,"pct_of_holder_assets":0.1718910272341541,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"三菱倉庫（株）","held_name_en":"Mitsubishi Logistics Corporation","held_sec_code":"9301","match_status":"matched","shares":1427500,"book_value_yen":1886000000,"prior_shares":1427500,"prior_book_value_yen":1380000000,"purpose_ja":"事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.41630529155813506,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.22169274044434936,"pct_of_holder_assets":0.1704450459324998,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）メディパルホールディングス","held_name_en":"MEDIPAL HOLDINGS CORPORATION","held_sec_code":"7459","match_status":"matched","shares":591038,"book_value_yen":1736000000,"prior_shares":591038,"prior_book_value_yen":1380000000,"purpose_ja":"取引先(特約店)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.28873567221808927,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.20406076214813917,"pct_of_holder_assets":0.15688897122949078,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"杏林製薬（株）","held_name_en":"KYORIN Pharmaceutical Co., Ltd.","held_sec_code":"4569","match_status":"matched","shares":965000,"book_value_yen":1587000000,"prior_shares":965000,"prior_book_value_yen":1449000000,"purpose_ja":"医薬品事業において、事業上の関係を維持・強化し、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":1.6607710441935306,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.18654633037390372,"pct_of_holder_assets":0.1434232703578352,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）大林組","held_name_en":"OBAYASHI CORPORATION","held_sec_code":"1802","match_status":"matched","shares":388800,"book_value_yen":1460000000,"prior_shares":388800,"prior_book_value_yen":771000000,"purpose_ja":"事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.056492278808819504,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.17161792208311244,"pct_of_holder_assets":0.13194579377595422,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"長瀬産業（株）","held_name_en":"NAGASE & CO., LTD.","held_sec_code":"8012","match_status":"matched","shares":295000,"book_value_yen":1363000000,"prior_shares":295000,"prior_book_value_yen":783000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.28727745066289756,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1602159094515632,"pct_of_holder_assets":0.12317953213467508,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）朝日工業社","held_name_en":"ASAHI KOGYOSHA CO., LTD.","held_sec_code":"1975","match_status":"matched","shares":360000,"book_value_yen":1228000000,"prior_shares":360000,"prior_book_value_yen":699000000,"purpose_ja":"事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":1.391266709692878,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.14434712898497404,"pct_of_holder_assets":0.11097906490196699,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）椿本チエイン","held_name_en":"ＴＳＵＢＡＫＩＭＯＴＯ　ＣＨＡＩＮ　ＣＯ．","held_sec_code":"6371","match_status":"matched","shares":442200,"book_value_yen":1017000000,"prior_shares":442200,"prior_book_value_yen":818000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.42516827342039004,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.11954481284830504,"pct_of_holder_assets":0.091910186486401,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日本精化（株）","held_name_en":"Nippon Fine Chemical Co., Ltd.","held_sec_code":"4362","match_status":"matched","shares":394100,"book_value_yen":958000000,"prior_shares":394100,"prior_book_value_yen":789000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":1.8173813503839766,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1126095680517957,"pct_of_holder_assets":0.0865781304365508,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"日本光電工業（株）","held_name_en":"NIHON KOHDEN CORPORATION","held_sec_code":"6849","match_status":"matched","shares":481200,"book_value_yen":700000000,"prior_shares":481200,"prior_book_value_yen":964000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.2990629856976794,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.08228256538231418,"pct_of_holder_assets":0.06326168194737532,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"三浦工業（株）","held_name_en":"MIURA CO., LTD.","held_sec_code":"6005","match_status":"matched","shares":209400,"book_value_yen":650000000,"prior_shares":209400,"prior_book_value_yen":619000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.18096589326994583,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07640523928357745,"pct_of_holder_assets":0.05874299037970565,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）いよぎんホールディングス","held_name_en":"Iyogin Holdings, Inc.","held_sec_code":"5830","match_status":"matched","shares":229228,"book_value_yen":649000000,"prior_shares":229228,"prior_book_value_yen":403000000,"purpose_ja":"取引先(金融機関)として、取引関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有（注７）","pct_outstanding":0.07913650087004477,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07628769276160273,"pct_of_holder_assets":0.05865261654835226,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":["7"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）三井住友フィナンシャルグループ","held_name_en":"Sumitomo Mitsui Financial Group, Inc.","held_sec_code":"8316","match_status":"matched","shares":124911,"book_value_yen":625000000,"prior_shares":124911,"prior_book_value_yen":474000000,"purpose_ja":"取引先(金融機関)として、取引関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有（注８）","pct_outstanding":0.003272114433635711,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07346657623420909,"pct_of_holder_assets":0.05648364459587082,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":["8"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"第一実業（株）","held_name_en":"DAIICHI　JITSUGYO　CO.,　LTD.","held_sec_code":"8059","match_status":"matched","shares":169700,"book_value_yen":549000000,"prior_shares":169700,"prior_book_value_yen":370000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.53149341192462,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06453304056412927,"pct_of_holder_assets":0.04961523341301293,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"北興化学工業（株）","held_name_en":"HOKKO CHEMICAL INDUSTRY CO.,LTD.","held_sec_code":"4992","match_status":"matched","shares":300000,"book_value_yen":512000000,"prior_shares":300000,"prior_book_value_yen":386000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":1.1636778441673228,"pct_unavailable":null,"pct_basis_period_end":"2025-11-30","pct_share_classes":1,"pct_of_holder_equity":0.06018381925106409,"pct_of_holder_assets":0.046271401652937375,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"東海東京フィナンシャル・ＨＤ（株）","held_name_en":null,"held_sec_code":null,"match_status":"unmatched","shares":593098,"book_value_yen":422000000,"prior_shares":593098,"prior_book_value_yen":287000000,"purpose_ja":"取引先(金融機関)として、取引関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有（注９）","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.04960463227333798,"pct_of_holder_assets":0.03813775683113198,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"インフロニア・ホールディングス株式会社","held_name_en":"INFRONEER Holdings Inc.","held_sec_code":"5076","match_status":"matched","shares":158700,"book_value_yen":342000000,"prior_shares":158700,"prior_book_value_yen":192000000,"purpose_ja":"事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有（注10）","pct_outstanding":0.0607121746969376,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":2,"pct_of_holder_equity":0.04020091051535921,"pct_of_holder_assets":0.030907850322860513,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":["10"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ゼリア新薬工業（株）","held_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","held_sec_code":"4559","match_status":"matched","shares":151800,"book_value_yen":333000000,"prior_shares":151800,"prior_book_value_yen":343000000,"purpose_ja":"医薬品事業において、事業上の関係を維持・強化し、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.34437785010670496,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.039142991817586605,"pct_of_holder_assets":0.030094485840679974,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"ダイト（株）（注11）","held_name_en":"Daito Pharmaceutical Co.,Ltd.","held_sec_code":"4577","match_status":"matched","shares":193600,"book_value_yen":280000000,"prior_shares":96800,"prior_book_value_yen":212000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.6713322408002169,"pct_unavailable":null,"pct_basis_period_end":"2026-05-31","pct_share_classes":1,"pct_of_holder_equity":0.03291302615292568,"pct_of_holder_assets":0.025304672778950127,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":2.0,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）ほくやく・竹山ホールディングス","held_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","held_sec_code":"3055","match_status":"matched","shares":249606,"book_value_yen":230000000,"prior_shares":249606,"prior_book_value_yen":221000000,"purpose_ja":"取引先(特約店)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":1.2142613907239665,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.027035700054188948,"pct_of_holder_assets":0.02078598121128046,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）バイタルケーエスケー・ＨＤ","held_name_en":null,"held_sec_code":null,"match_status":"unmatched","shares":141561,"book_value_yen":207000000,"prior_shares":141561,"prior_book_value_yen":178000000,"purpose_ja":"取引先(特約店)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有（注12）","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.02433213004877005,"pct_of_holder_assets":0.018707383090152414,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"塩野義製薬（株）","held_name_en":"Shionogi & Co., Ltd.","held_sec_code":"4507","match_status":"matched","shares":15636,"book_value_yen":54000000,"prior_shares":15636,"prior_book_value_yen":35000000,"purpose_ja":"医薬品事業において、事業上の関係を維持・強化し、中長期的に企業価値の向上を図るために株式を保有しています。定量的な保有効果については記載が困難であります。保有の合理性は、「保有の合理性を検証する方法」（注３）に記載したような観点に着目し、取締役会において、保有の適否を検証しています。","reciprocal":"有","pct_outstanding":0.0018181913427661098,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.006347512186635666,"pct_of_holder_assets":0.004880186893083239,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）大和証券グループ本社","held_name_en":"Daiwa Securities Group Inc.","held_sec_code":"8601","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":322751,"prior_book_value_yen":321000000,"purpose_ja":"取引先(金融機関)として、取引関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有していましたが、当事業年度に全株式を売却しています。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）ヤクルト本社","held_name_en":"YAKULT HONSHA CO.,LTD.","held_sec_code":"2267","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":656000,"prior_book_value_yen":1872000000,"purpose_ja":"医薬品事業において、事業上の関係を維持・強化し、中長期的に企業価値の向上を図るために株式を保有していましたが、当事業年度に全株式を売却しています。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)meito（注13）","held_name_en":"MEITO CO.,LTD.","held_sec_code":"2207","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":182300,"prior_book_value_yen":364000000,"purpose_ja":"取引先(原材料等の仕入先)として、事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有していましたが、当事業年度に全株式を売却しています。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"（株）日立製作所","held_name_en":"Hitachi, Ltd.","held_sec_code":"6501","match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":385000,"prior_book_value_yen":1331000000,"purpose_ja":"事業上の関係を維持・強化することで、企業基盤の安定化を図り、中長期的に企業価値の向上を図るために株式を保有していましたが、当事業年度に全株式を売却しています。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"久光製薬（株）","held_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","held_sec_code":null,"match_status":"matched","shares":null,"book_value_yen":null,"prior_shares":448300,"prior_book_value_yen":1814000000,"purpose_ja":"医薬品事業において、事業上の関係を維持・強化し、中長期的に企業価値の向上を図るために株式を保有していましたが、当事業年度に全株式を売却しています。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2025-02-28","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":850727000000,"holder_total_assets_yen":1106515000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"株式会社三菱ＵＦＪフィナンシャル・グループ","holder_name_en":"Mitsubishi UFJ Financial Group, Inc.","holder_sec_code":"8306","doc_id":"S100YJQO","period_end":"2026-03-31","holder_table":"largest","shares":8640740,"book_value_yen":21692000000,"prior_shares":8640740,"prior_book_value_yen":13846000000,"purpose_ja":"発行会社グループとの、主に金融取引(預金・貸出・為替等)における総合的な取引関係維持・拡大のために保有","reciprocal":"有","pct_outstanding":1.8065308441860508,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.09135723187755873,"pct_of_holder_assets":0.005024418553725891,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":23744152000000,"holder_total_assets_yen":431731548000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ＭＳ＆ＡＤインシュアランスグループホールディングス株式会社","holder_name_en":"MS&AD Insurance Group Holdings, Inc.","holder_sec_code":"8725","doc_id":"S100YNCJ","period_end":"2026-03-31","holder_table":"second_largest","shares":5212475,"book_value_yen":13085000000,"prior_shares":7779775,"prior_book_value_yen":12467000000,"purpose_ja":"保険取引先との関係の維持・強化を目的として安定保有していたが、保有方針については③a.(a)に記載のとおり","reciprocal":"無","pct_outstanding":1.0897789844444672,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2711838412978691,"pct_of_holder_assets":0.04568654907341149,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":4825140000000,"holder_total_assets_yen":28640815000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"三井住友トラストグループ株式会社","holder_name_en":"Sumitomo Mitsui Trust Group, Inc.","holder_sec_code":"8309","doc_id":"S100YBGM","period_end":"2026-03-31","holder_table":"largest","shares":3500000,"book_value_yen":8786000000,"prior_shares":3500000,"prior_book_value_yen":5608000000,"purpose_ja":"同上","reciprocal":"無","pct_outstanding":0.7317495902724973,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2446693357698159,"pct_of_holder_assets":0.010691909926074192,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":3590969000000,"holder_total_assets_yen":82174280000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"参天製薬株式会社","holder_name_en":"SANTEN PHARMACEUTICAL CO., LTD.","holder_sec_code":"4536","doc_id":"S100YDH1","period_end":"2026-03-31","holder_table":"reporting","shares":3457400,"book_value_yen":8680000000,"prior_shares":3457400,"prior_book_value_yen":5540000000,"purpose_ja":"当社眼科薬に関する技術導入契約があり、眼科領域における事業関係の強化を図ることを目的に保有しています。（注）","reciprocal":"有","pct_outstanding":0.7228431524023234,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":2.922667169491126,"pct_of_holder_assets":2.051849382908662,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":296989000000,"holder_total_assets_yen":423033000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社Ｔ＆Ｄホールディングス","holder_name_en":"T&D Holdings, Inc.","holder_sec_code":"8795","doc_id":"S100YZ3S","period_end":"2026-03-31","holder_table":"second_largest","shares":3274800,"book_value_yen":8221000000,"prior_shares":3274800,"prior_book_value_yen":5247000000,"purpose_ja":"2030年度をめどに業務提携先及び協業先等を除き政策保有株をゼロとする方針の下、保有継続については、引き続き検討を行ってまいります。","reciprocal":"有","pct_outstanding":0.6846667309212497,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5082104328721462,"pct_of_holder_assets":0.0474699377751745,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":1617637000000,"holder_total_assets_yen":17318329000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"杏林製薬株式会社","holder_name_en":"KYORIN Pharmaceutical Co., Ltd.","holder_sec_code":"4569","doc_id":"S100YDHG","period_end":"2026-03-31","holder_table":"reporting","shares":1812000,"book_value_yen":4549000000,"prior_shares":1812000,"prior_book_value_yen":2903000000,"purpose_ja":"医薬品事業において、事業上の関係を維持・強化するために保有するものであり、当社の持続成長や企業価値向上の観点から総合的に保有の適否を検証しております","reciprocal":"有","pct_outstanding":0.3788372164496472,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":3.1939617342460944,"pct_of_holder_assets":2.327389936302474,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":142425000000,"holder_total_assets_yen":195455000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"largest","shares":1753500,"book_value_yen":4402000000,"prior_shares":1753500,"prior_book_value_yen":2809000000,"purpose_ja":"・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１","reciprocal":"有","pct_outstanding":0.36660654472652116,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.8667009251766578,"pct_of_holder_assets":0.2921004156558391,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社メディパルホールディングス","holder_name_en":"MEDIPAL HOLDINGS CORPORATION","holder_sec_code":"7459","doc_id":"S100YI1C","period_end":"2026-03-31","holder_table":"reporting","shares":1677615,"book_value_yen":4211000000,"prior_shares":1677615,"prior_book_value_yen":2688000000,"purpose_ja":"・当社グループの医療用医薬品等卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.35074116825285584,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5294198257729769,"pct_of_holder_assets":0.21909446504217997,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社大林組","holder_name_en":"OBAYASHI CORPORATION","holder_sec_code":"1802","doc_id":"S100YITC","period_end":"2026-03-31","holder_table":"reporting","shares":1637500,"book_value_yen":4110000000,"prior_shares":2183400,"prior_book_value_yen":3498000000,"purpose_ja":"・同社株式は主に国内建築事業における収益の維持・向上のため保有している。","reciprocal":"有","pct_outstanding":0.34235427259177553,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3121994795156123,"pct_of_holder_assets":0.13074810502731235,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":1316466000000,"holder_total_assets_yen":3143449000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日産化学株式会社","holder_name_en":"Nissan Chemical Corporation","holder_sec_code":"4021","doc_id":"S100YIML","period_end":"2026-03-31","holder_table":"reporting","shares":1453600,"book_value_yen":3649000000,"prior_shares":1453600,"prior_book_value_yen":2329000000,"purpose_ja":"主にヘルスケアセグメントにおける営業取引関係の維持・発展を保有目的としております。","reciprocal":"無","pct_outstanding":0.3039060584057434,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.4086029391895805,"pct_of_holder_assets":1.0276615278896468,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":259051000000,"holder_total_assets_yen":355078000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"日清食品ホールディングス株式会社","holder_name_en":"NISSIN FOODS HOLDINGS CO.,LTD.","holder_sec_code":"2897","doc_id":"S100YEWB","period_end":"2026-03-31","holder_table":"reporting","shares":1356900,"book_value_yen":3406000000,"prior_shares":2035300,"prior_book_value_yen":3261000000,"purpose_ja":"各種事業・取引における企業価値向上のための関係の維持強化","reciprocal":"有","pct_outstanding":0.28368886258307185,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.6585867648423723,"pct_of_holder_assets":0.347127737096092,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":517168000000,"holder_total_assets_yen":981195000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社スズケン","holder_name_en":"SUZUKEN CO.,LTD.","holder_sec_code":"9987","doc_id":"S100YFRU","period_end":"2026-03-31","holder_table":"reporting","shares":1243000,"book_value_yen":3120000000,"prior_shares":1243000,"prior_book_value_yen":1991000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"有","pct_outstanding":0.25987564020248977,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7499783660086728,"pct_of_holder_assets":0.2699508377993469,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"前田建設工業株式会社","holder_name_en":"ＭＡＥＤＡ　ＣＯＲＰＯＲＡＴＩＯＮ","holder_sec_code":"1824","doc_id":"S100G4IW","period_end":"2019-03-31","holder_table":"reporting","shares":1220000,"book_value_yen":2646000000,"prior_shares":1220000,"prior_book_value_yen":4018000000,"purpose_ja":null,"reciprocal":"有","pct_outstanding":0.23726937951140012,"pct_unavailable":null,"pct_basis_period_end":"2019-03-31","pct_share_classes":1,"pct_of_holder_equity":1.0475805876903341,"pct_of_holder_assets":0.3687136825383554,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":252582000000,"holder_total_assets_yen":717630000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"久光製薬株式会社","holder_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","holder_sec_code":"4530","doc_id":"S100VT69","period_end":"2025-02-28","holder_table":"reporting","shares":1583500,"book_value_yen":2570000000,"prior_shares":1583500,"prior_book_value_yen":3939000000,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"有","pct_outstanding":0.3370776949718268,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.9198051587827076,"pct_of_holder_assets":0.7491226229202373,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大塚ホールディングス株式会社","holder_name_en":"Otsuka Holdings Co., Ltd.","holder_sec_code":"4578","doc_id":"S100XUA7","period_end":"2025-12-31","holder_table":"reporting","shares":1176500,"book_value_yen":2555000000,"prior_shares":1176500,"prior_book_value_yen":1922000000,"purpose_ja":"子会社における事業上の関係の維持・強化のため、事業基盤の安定化に資する協力関係の構築を図るため、保有しております。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.2459723979873123,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0842276963082226,"pct_of_holder_assets":0.06086866614477642,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社朝日工業社","holder_name_en":"ASAHI KOGYOSHA CO., LTD.","holder_sec_code":"1975","doc_id":"S100YIGB","period_end":"2026-03-31","holder_table":"reporting","shares":965605,"book_value_yen":2424000000,"prior_shares":965605,"prior_book_value_yen":1547000000,"purpose_ja":"工事受注を主とした取引関係の維持発展等、中長期的な企業価値の向上を実現するため。","reciprocal":"有","pct_outstanding":0.2018803037471642,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":4.76621180541901,"pct_of_holder_assets":2.407221664994985,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":50858000000,"holder_total_assets_yen":100697000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日本新薬株式会社","holder_name_en":"Nippon Shinyaku Co., Ltd.","holder_sec_code":"4516","doc_id":"S100YGRG","period_end":"2026-03-31","holder_table":"reporting","shares":941000,"book_value_yen":2362000000,"prior_shares":941000,"prior_book_value_yen":1507000000,"purpose_ja":"協力関係の構築を目的に株式を保有しています。定量的な保有効果を示す事が困難なことから記載は省略していますが、「保有目的の合理性」と保有資産としての「経済的合理性」を検証し、2026年4月の取締役会において検証結果を確認、保有の可否を判断しています。","reciprocal":"有","pct_outstanding":0.19673610412754855,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.8101498537134155,"pct_of_holder_assets":0.6819513857009635,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":291551000000,"holder_total_assets_yen":346359000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"三菱倉庫株式会社","holder_name_en":"Mitsubishi Logistics Corporation","holder_sec_code":"9301","doc_id":"S100YA7K","period_end":"2026-03-31","holder_table":"reporting","shares":931500,"book_value_yen":2338000000,"prior_shares":931500,"prior_book_value_yen":1492000000,"purpose_ja":"同社株式は、主に物流事業(倉庫、陸上運送事業)における営業取引関係の維持・強化を目的とするほか、資本コスト、配当・取引額等に加え、事業上の関係等を総合的に判断し保有しています。定量的な保有効果については取引先との営業機密があるため記載しませんが、定量的及び定性的評価に基づき、保有の合理性があると判断しています。","reciprocal":"有","pct_outstanding":0.19474992666823748,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.6080355354899784,"pct_of_holder_assets":0.3654346922252128,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":384517000000,"holder_total_assets_yen":639786000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"キッコーマン株式会社","holder_name_en":"KIKKOMAN CORPORATION","holder_sec_code":"2801","doc_id":"S100YE5V","period_end":"2026-03-31","holder_table":"reporting","shares":870000,"book_value_yen":2184000000,"prior_shares":870000,"prior_book_value_yen":1394000000,"purpose_ja":"相互の取り組みによる将来的な企業価値向上が保有の目的です。定量的な保有効果については営業秘密との判断により記載しませんが、取引金額、投資収益から評価を行うとともに、将来的な取り組みを含めた総合的な判断により保有効果を評価しております。","reciprocal":"有","pct_outstanding":0.18189204101059217,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3893575600259572,"pct_of_holder_assets":0.29055690072639223,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":560924000000,"holder_total_assets_yen":751660000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社伊予銀行","holder_name_en":"The Iyo Bank, Ltd.","holder_sec_code":"8385","doc_id":"S100OLYJ","period_end":"2022-03-31","holder_table":"reporting","shares":704110,"book_value_yen":2158000000,"prior_shares":704110,"prior_book_value_yen":2034000000,"purpose_ja":"緊密な関係の維持強化","reciprocal":"有","pct_outstanding":0.1441933264893161,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":0.29489011995113407,"pct_of_holder_assets":0.025255134791382406,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":731798000000,"holder_total_assets_yen":8544797000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社きんでん","holder_name_en":"ＫＩＮＤＥＮ　ＣＯＲＰＯＲＡＴＩＯＮ","holder_sec_code":"1944","doc_id":"S100YFY8","period_end":"2026-03-31","holder_table":"reporting","shares":845000,"book_value_yen":2121000000,"prior_shares":845000,"prior_book_value_yen":1354000000,"purpose_ja":"保有先企業は、当社が設備工事を請け負っている重要顧客の一つであり、関係強化により中長期的な工事受注獲得による収益を維持向上させるため保有している。","reciprocal":"無","pct_outstanding":0.1766652582229315,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.32044357488725556,"pct_of_holder_assets":0.23211708068722414,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":661895000000,"holder_total_assets_yen":913763000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"三機工業株式会社","holder_name_en":"Sanki Engineering Co., Ltd.","holder_sec_code":"1961","doc_id":"S100YH3A","period_end":"2026-03-31","holder_table":"reporting","shares":783250,"book_value_yen":1966000000,"prior_shares":1174750,"prior_book_value_yen":1882000000,"purpose_ja":"建築設備事業において主に産業空調事業及び電気事業等の建築設備工事の受注先であります。当社で定める基準を充足しており、同社との良好な取引関係を維持・強化し、受注獲得につなげるため、継続して保有しております。なお、当事業年度に一部売却を行いました。","reciprocal":"無","pct_outstanding":0.16375510473740956,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.6189464495993808,"pct_of_holder_assets":0.8957413558225467,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":121437000000,"holder_total_assets_yen":219483000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ダイキン工業株式会社","holder_name_en":"DAIKIN INDUSTRIES,LTD.","holder_sec_code":"6367","doc_id":"S100YFQL","period_end":"2026-03-31","holder_table":"reporting","shares":740000,"book_value_yen":1857000000,"prior_shares":1480000,"prior_book_value_yen":2371000000,"purpose_ja":"同社は当社の空調事業における販売先であり、相互の事業拡大や取引関係の強化を目的に株式を保有しております。","reciprocal":"有","pct_outstanding":0.15471277051475657,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.055992121905432714,"pct_of_holder_assets":0.031966315731489836,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":3316538000000,"holder_total_assets_yen":5809240000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社テクノ菱和","holder_name_en":"TECHNO RYOWA LTD.","holder_sec_code":"1965","doc_id":"S100YF2U","period_end":"2026-03-31","holder_table":"reporting","shares":740000,"book_value_yen":1857000000,"prior_shares":740000,"prior_book_value_yen":1185000000,"purpose_ja":"設備工事業の取引先である発行会社との取引関係の維持・強化が当社の企業価値向上に資すると判断し、保有しております。","reciprocal":"無","pct_outstanding":0.15471277051475657,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":2.798752091151603,"pct_of_holder_assets":1.8410199468612445,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":66351000000,"holder_total_assets_yen":100868000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社いよぎんホールディングス","holder_name_en":"Iyogin Holdings, Inc.","holder_sec_code":"5830","doc_id":"S100YBIB","period_end":"2026-03-31","holder_table":"largest","shares":704110,"book_value_yen":1767000000,"prior_shares":704110,"prior_book_value_yen":1128000000,"purpose_ja":"当社グループの主な営業基盤である瀬戸内圏域に本社等を有し、地域経済の成長・活性化に重要な企業であることから、総合的な関係の維持強化を図ることにより当社グループの中長期的な企業価値の向上に資するため保有しております。","reciprocal":"有","pct_outstanding":0.14720920114479089,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.20127989866519647,"pct_of_holder_assets":0.01852237758983091,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":877882000000,"holder_total_assets_yen":9539812000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ＣＫＤ株式会社","holder_name_en":"CKD Corporation","holder_sec_code":"6407","doc_id":"S100YGB2","period_end":"2026-03-31","holder_table":"reporting","shares":703000,"book_value_yen":1764000000,"prior_shares":703000,"prior_book_value_yen":1126000000,"purpose_ja":"医薬品メーカーで、長年にわたり薬品包装システムで取引があり、取引強化を図る目的で保有しています。","reciprocal":"有","pct_outstanding":0.14697713198901874,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.148901249202152,"pct_of_holder_assets":0.7780487912456279,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":153538000000,"holder_total_assets_yen":226721000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社日立製作所","holder_name_en":"Hitachi, Ltd.","holder_sec_code":"6501","doc_id":"S100YGBO","period_end":"2026-03-31","holder_table":"reporting","shares":600000,"book_value_yen":1506000000,"prior_shares":600000,"prior_book_value_yen":961000000,"purpose_ja":"インダストリアルデジタル事業における製品・サービスの販売・提供に係る取引関係を維持・強化するため、保有しています。","reciprocal":"有","pct_outstanding":0.12544278690385668,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.02223663649758505,"pct_of_holder_assets":0.01001246838194123,"holder_equity_basis":"ifrs_consolidated","holder_equity_yen":6772607000000,"holder_total_assets_yen":15041246000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社　島津製作所","holder_name_en":"Shimadzu Corporation","holder_sec_code":"7701","doc_id":"S100YGJF","period_end":"2026-03-31","holder_table":"reporting","shares":583000,"book_value_yen":1463000000,"prior_shares":583000,"prior_book_value_yen":934000000,"purpose_ja":"計測機器での取引および協力関係の維持・強化により、中長期的な企業価値向上を図るため保有しています。","reciprocal":"有","pct_outstanding":0.1218885746082474,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.25886199806782434,"pct_of_holder_assets":0.19824439210924988,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":565166000000,"holder_total_assets_yen":737978000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社愛知銀行","holder_name_en":"The Aichi Bank,Ltd.","holder_sec_code":"8527","doc_id":"S100OASF","period_end":"2022-03-31","holder_table":"reporting","shares":440000,"book_value_yen":1349000000,"prior_shares":440000,"prior_book_value_yen":1271000000,"purpose_ja":"保有に関する経済合理性を有し、業界内の有力企業である同社との関係維持・向上を通じた、当行グループの企業価値向上のため。","reciprocal":"有","pct_outstanding":0.09010674987615441,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5632285647483216,"pct_of_holder_assets":0.03122143869037521,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":239512000000,"holder_total_assets_yen":4320749000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"東邦ホールディングス株式会社","holder_name_en":"TOHO HOLDINGS CO.,LTD.","holder_sec_code":"8129","doc_id":"S100YHSN","period_end":"2026-03-31","holder_table":"reporting","shares":428920,"book_value_yen":1076000000,"prior_shares":1177920,"prior_book_value_yen":1887000000,"purpose_ja":"同上","reciprocal":"有","pct_outstanding":0.08967486693133701,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3962291942848726,"pct_of_holder_assets":0.14525210554806348,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":271560000000,"holder_total_assets_yen":740781000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社バイタルケーエスケー・ホールディングス","holder_name_en":"VITAL KSK HOLDINGS,INC.","holder_sec_code":"3151","doc_id":"S100YDSN","period_end":"2026-03-31","holder_table":"largest","shares":387810,"book_value_yen":973000000,"prior_shares":580810,"prior_book_value_yen":930000000,"purpose_ja":"①商品の確保や仕入の円滑化のため　②該当なし　③ＡがＢを上回っております　④該当なし","reciprocal":"有","pct_outstanding":0.08107994531530777,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.8196652261450462,"pct_of_holder_assets":0.3035237453520002,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":118707000000,"holder_total_assets_yen":320568000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"三浦工業株式会社","holder_name_en":"MIURA CO., LTD.","holder_sec_code":"6005","doc_id":"S100YEGC","period_end":"2026-03-31","holder_table":"reporting","shares":384800,"book_value_yen":966000000,"prior_shares":384800,"prior_book_value_yen":616000000,"purpose_ja":"取引先(販売先)として、事業上の取引関係を維持・強化するために株式を保有しております。","reciprocal":"有","pct_outstanding":0.08045064066767342,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.397274189104159,"pct_of_holder_assets":0.20276014063073936,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":243157000000,"holder_total_assets_yen":476425000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社椿本チエイン","holder_name_en":"ＴＳＵＢＡＫＩＭＯＴＯ　ＣＨＡＩＮ　ＣＯ．","holder_sec_code":"6371","doc_id":"S100YKVK","period_end":"2026-03-31","holder_table":"reporting","shares":372000,"book_value_yen":933000000,"prior_shares":372000,"prior_book_value_yen":596000000,"purpose_ja":"（保有目的）マテハン事業の営業取引(販売)の関係強化のため（定量的な保有効果）（注）１","reciprocal":"有","pct_outstanding":0.07777452788039114,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3070947780721821,"pct_of_holder_assets":0.2029213717745724,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":303815000000,"holder_total_assets_yen":459784000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"長瀬産業株式会社","holder_name_en":"NAGASE & CO., LTD.","holder_sec_code":"8012","doc_id":"S100YK28","period_end":"2026-03-31","holder_table":"reporting","shares":365000,"book_value_yen":916000000,"prior_shares":365000,"prior_book_value_yen":584000000,"purpose_ja":"生活関連セグメントを中心に、医療・医薬・検査薬関連の取引を行っており、同社との良好な関係維持、取引の強化および事業の拡大を図るために保有しております。(注)2","reciprocal":"有","pct_outstanding":0.07631102869984614,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.21104775070560453,"pct_of_holder_assets":0.10510300323799864,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":434025000000,"holder_total_assets_yen":871526000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"塩野義製薬株式会社","holder_name_en":"Shionogi & Co., Ltd.","holder_sec_code":"4507","doc_id":"S100Z43Z","period_end":"2026-03-31","holder_table":"reporting","shares":344095,"book_value_yen":863000000,"prior_shares":344095,"prior_book_value_yen":551000000,"purpose_ja":"同社は当社の取引先の一つであるため、医薬事業戦略における取引関係維持・強化のために株式を保有しております。2026年５月の取締役会において、個別の政策保有株式について、保有目的、保有に伴う便益・リスク、資本コスト等を総合的に検証し、経済合理性・戦略妥当性を確認しております。","reciprocal":"有","pct_outstanding":0.07194039293280427,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.05121008298644387,"pct_of_holder_assets":0.033490242037821076,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":1685215000000,"holder_total_assets_yen":2576870000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"養命酒製造株式会社","holder_name_en":"YOMEISHU SEIZO CO., LTD.","holder_sec_code":"2540","doc_id":"S100YK3W","period_end":"2026-03-31","holder_table":"reporting","shares":331500,"book_value_yen":832230000,"prior_shares":331500,"prior_book_value_yen":531228000,"purpose_ja":"医薬品分野における取引・協力関係の構築による企業価値向上を図るため株式を保有しております。","reciprocal":"無","pct_outstanding":0.06930713976438081,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.7957034779442504,"pct_of_holder_assets":1.5398582149223756,"holder_equity_basis":"parent_only","holder_equity_yen":46345625000,"holder_total_assets_yen":54045885000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社大和証券グループ本社","holder_name_en":"Daiwa Securities Group Inc.","holder_sec_code":"8601","doc_id":"S100YCMP","period_end":"2026-03-31","holder_table":"reporting","shares":306800,"book_value_yen":770000000,"prior_shares":306800,"prior_book_value_yen":491000000,"purpose_ja":"証券関連ビジネスの拡大を目的とした良好な関係の維持・強化を図るため、継続保有していましたが、有価証券報告書提出日現在において、全株式を売却しております。","reciprocal":"無","pct_outstanding":0.06414307837017205,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.03763792221072446,"pct_of_holder_assets":0.002022183829326004,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":2045809000000,"holder_total_assets_yen":38077646000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"日本光電工業株式会社","holder_name_en":"NIHON KOHDEN CORPORATION","holder_sec_code":"6849","doc_id":"S100YHO8","period_end":"2026-03-31","holder_table":"reporting","shares":275000,"book_value_yen":690000000,"prior_shares":275000,"prior_book_value_yen":440000000,"purpose_ja":"同株式は商品販売における円滑な業務推進のため保有しています。当社は保有株式について資本コストを踏まえ、配当・取引額等に加え、経営戦略上の重要性や事業上の関係等を総合的に判断し、保有しています。定量的な保有効果については、取引先との営業秘密との判断により記載しませんが、上記方針に基づいた十分な定量的効果があると判断しています。","reciprocal":"有","pct_outstanding":0.05749461066426764,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.383708514992437,"pct_of_holder_assets":0.26896600113823294,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":179824000000,"holder_total_assets_yen":256538000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社　りそなホールディングス","holder_name_en":"Resona Holdings, Inc.","holder_sec_code":"8308","doc_id":"S100YDP3","period_end":"2026-03-31","holder_table":"largest","shares":273130,"book_value_yen":685000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"事業上の関係を総合的に勘案し、中長期的かつ安定的な取引関係の構築を図るため。","reciprocal":"無","pct_outstanding":0.057103647311750626,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.02339190872169878,"pct_of_holder_assets":0.0008977967569536522,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":2928363000000,"holder_total_assets_yen":76297892000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社ほくやく・竹山ホールディングス","holder_name_en":"HOKUYAKU TAKEYAMA Holdings,Inc.","holder_sec_code":"3055","doc_id":"S100YJPG","period_end":"2026-03-31","holder_table":"reporting","shares":263850,"book_value_yen":662000000,"prior_shares":263850,"prior_book_value_yen":422000000,"purpose_ja":"（保有目的）主として医薬品卸売事業における安定的な商品取引関係および医薬品専門情報収集等の強化のため （定量的な保有効果）　（注）","reciprocal":"有","pct_outstanding":0.05516346554097097,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.0237693889859734,"pct_of_holder_assets":0.4252175867938465,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":64663000000,"holder_total_assets_yen":155685000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社イチネンホールディングス","holder_name_en":"ICHINEN HOLDINGS CO., LTD.","holder_sec_code":"9619","doc_id":"S100YCGP","period_end":"2026-03-31","holder_table":"reporting","shares":250000,"book_value_yen":627000000,"prior_shares":250000,"prior_book_value_yen":400000000,"purpose_ja":"・当社グループにおいて主に自動車リース関連事業の取引先として関係の維持・強化を図るため。","reciprocal":"無","pct_outstanding":0.05226782787660695,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.8690830965416869,"pct_of_holder_assets":0.29630959863518,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":72145000000,"holder_total_assets_yen":211603000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社ミューチュアル","holder_name_en":"Mutual Corporation","holder_sec_code":"2773","doc_id":"S100OGUO","period_end":"2022-03-31","holder_table":"reporting","shares":167976,"book_value_yen":515016000,"prior_shares":166596,"prior_book_value_yen":481463000,"purpose_ja":"（保有目的）営業活動の円滑な推進（定量的な保有効果）（注）（株式数が増加した理由）取引先持株会を通じた株式の取得","reciprocal":"有","pct_outstanding":0.03439948049362935,"pct_unavailable":null,"pct_basis_period_end":"2022-03-31","pct_share_classes":1,"pct_of_holder_equity":4.615377583959847,"pct_of_holder_assets":3.0754726197686195,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":11158697000,"holder_total_assets_yen":16745914000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"日本精化株式会社","holder_name_en":"Nippon Fine Chemical Co., Ltd.","holder_sec_code":"4362","doc_id":"S100YCCG","period_end":"2026-03-31","holder_table":"reporting","shares":195000,"book_value_yen":489547000,"prior_shares":195000,"prior_book_value_yen":312487000,"purpose_ja":"機能性製品セグメントにおける取引先であり、事業関係及び取引関係の維持・強化等を目的に保有しております","reciprocal":"有","pct_outstanding":0.04076890574375342,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.9344283260164153,"pct_of_holder_assets":0.748302532825851,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":52390000000,"holder_total_assets_yen":65421000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"second_largest","shares":159365,"book_value_yen":400000000,"prior_shares":159365,"prior_book_value_yen":255000000,"purpose_ja":"・良好な取引関係の維持発展・当社グループの取引先・検証実施(注)１","reciprocal":"有","pct_outstanding":0.03331864955822186,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07875519538179535,"pct_of_holder_assets":0.026542518460321587,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"第一実業株式会社","holder_name_en":"DAIICHI　JITSUGYO　CO.,　LTD.","holder_sec_code":"8059","doc_id":"S100YGOV","period_end":"2026-03-31","holder_table":"reporting","shares":150000,"book_value_yen":376000000,"prior_shares":150000,"prior_book_value_yen":240000000,"purpose_ja":"医薬品製造設備の取引を行っており、医薬品関連事業の拡大、創出を図るため保有しております。","reciprocal":"有","pct_outstanding":0.03136069672596417,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.41454890243767983,"pct_of_holder_assets":0.21407546160021407,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":90701000000,"holder_total_assets_yen":175639000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"ゼリア新薬工業株式会社","holder_name_en":"ZERIA PHARMACEUTICAL CO., LTD.","holder_sec_code":"4559","doc_id":"S100YKC2","period_end":"2026-03-31","holder_table":"reporting","shares":146800,"book_value_yen":368541000,"prior_shares":146800,"prior_book_value_yen":235247000,"purpose_ja":"（保有目的）医療用医薬品事業及びコンシューマーヘルスケア事業活動の円滑な推進（定量的な保有効果）（注）１","reciprocal":"有","pct_outstanding":0.0306916685291436,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.3393413863237524,"pct_of_holder_assets":0.20508915213050094,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":108604790000,"holder_total_assets_yen":179697949000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社山陰合同銀行","holder_name_en":"The San-in Godo Bank,Ltd.","holder_sec_code":"8381","doc_id":"S100YBU8","period_end":"2026-03-31","holder_table":"reporting","shares":137700,"book_value_yen":345000000,"prior_shares":137700,"prior_book_value_yen":220000000,"purpose_ja":"当行営業地域の関西エリアに本社を置く上場企業であり、預金・貸出金取引等の維持・強化を目的に保有しております。なお、定量的な保有効果も含め、経済合理性を踏まえた保有合理性を検証しております。","reciprocal":"無","pct_outstanding":0.028789119594435107,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1073886504203721,"pct_of_holder_assets":0.0038160698573066402,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":321263000000,"holder_total_assets_yen":9040715000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"北興化学工業株式会社","holder_name_en":"HOKKO CHEMICAL INDUSTRY CO.,LTD.","holder_sec_code":"4992","doc_id":"S100XVAV","period_end":"2025-11-30","holder_table":"reporting","shares":150000,"book_value_yen":330000000,"prior_shares":150000,"prior_book_value_yen":260000000,"purpose_ja":"ファインケミカル事業の強化分野における情報交換等協力関係を維持し、企業基盤の安定化を図るため。","reciprocal":"有","pct_outstanding":0.03136069672596417,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.6238185255198487,"pct_of_holder_assets":0.4252577319587629,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":52900000000,"holder_total_assets_yen":77600000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"インフロニア・ホールディングス株式会社","holder_name_en":"INFRONEER Holdings Inc.","holder_sec_code":"5076","doc_id":"S100YCIP","period_end":"2026-03-31","holder_table":"largest","shares":123000,"book_value_yen":308000000,"prior_shares":245000,"prior_book_value_yen":392000000,"purpose_ja":"前事業年度は同社との良好な関係の維持・強化を目的に保有していましたが、検証の結果、当事業年度において一部株式を売却しました。","reciprocal":"有","pct_outstanding":0.02571577131529062,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.05044210540107206,"pct_of_holder_assets":0.015224160941129949,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":610601000000,"holder_total_assets_yen":2023100000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"朝日印刷株式会社","holder_name_en":"ASAHI PRINTING CO.,LTD.","holder_sec_code":"3951","doc_id":"S100YEXW","period_end":"2026-03-31","holder_table":"reporting","shares":100000,"book_value_yen":251000000,"prior_shares":100000,"prior_book_value_yen":160000000,"purpose_ja":"医薬品パッケージ等の取引先であり、安定的・長期的な取引関係の維持・強化を目的に保有しております。定量的な保有効果については秘密保持の観点から記載しておりませんが、保有意義や取引状況、経済合理性を取締役会において検証し、保有の合理性があると判断しております。","reciprocal":"―","pct_outstanding":0.02090713115064278,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.6832720838437457,"pct_of_holder_assets":0.3628478496566679,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":36735000000,"holder_total_assets_yen":69175000000,"implausible":false,"reciprocal_held_both_ways":null},{"holder_name":"セコム株式会社","holder_name_en":"SECOM CO., LTD.","holder_sec_code":"9735","doc_id":"S100YICV","period_end":"2026-03-31","holder_table":"reporting","shares":100000,"book_value_yen":251000000,"prior_shares":100000,"prior_book_value_yen":160000000,"purpose_ja":"主にセキュリティサービス事業におけるサービスおよび商品の取引等、取引関係の維持拡大を目的に保有しております。定量的な保有効果は個別の取引条件等に関わるため記載しておりませんが、(1)に記載の方法で2025年10月に保有の妥当性の検証を行いました。","reciprocal":"無","pct_outstanding":0.02090713115064278,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.016736881552222405,"pct_of_holder_assets":0.011254964403372543,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":1499682000000,"holder_total_assets_yen":2230127000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社堀場製作所","holder_name_en":"HORIBA, Ltd.","holder_sec_code":"6856","doc_id":"S100XSIJ","period_end":"2025-12-31","holder_table":"reporting","shares":108500,"book_value_yen":235000000,"prior_shares":108500,"prior_book_value_yen":177000000,"purpose_ja":"・保有目的販売先として事業上の良好な信頼関係の維持及び、業務のより円滑な推進を目的に株式を継続的に保有しています。・定量的な保有効果（注）１","reciprocal":"無","pct_outstanding":0.022684237298447416,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06740477283157412,"pct_of_holder_assets":0.04534237350924888,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":348640000000,"holder_total_assets_yen":518279000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ダイト株式会社","holder_name_en":"Daito Pharmaceutical Co.,Ltd.","holder_sec_code":"4577","doc_id":"S100YYNI","period_end":"2026-05-31","holder_table":"reporting","shares":80000,"book_value_yen":191000000,"prior_shares":80000,"prior_book_value_yen":125000000,"purpose_ja":"(保有目的) 当社の製剤販売先であり、取引関係の維持・強化を目的として保有しております。","reciprocal":"有","pct_outstanding":0.016725704920514225,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.36079942574332236,"pct_of_holder_assets":0.2606049856053267,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":52938000000,"holder_total_assets_yen":73291000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"神戸天然物化学株式会社","holder_name_en":"KNC Laboratories Co., Ltd.","holder_sec_code":"6568","doc_id":"S100YACF","period_end":"2026-03-31","holder_table":"reporting","shares":25000,"book_value_yen":62762000,"prior_shares":25000,"prior_book_value_yen":40062000,"purpose_ja":"販売取引関係の維持強化を目的として保有しております。","reciprocal":"無","pct_outstanding":0.005226782787660695,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4457356826178992,"pct_of_holder_assets":0.2899729210144663,"holder_equity_basis":"parent_only","holder_equity_yen":14080542000,"holder_total_assets_yen":21644090000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"大塚ホールディングス株式会社","holder_name_en":"Otsuka Holdings Co., Ltd.","holder_sec_code":"4578","doc_id":"S100XUA7","period_end":"2025-12-31","holder_table":"largest","shares":26000,"book_value_yen":56000000,"prior_shares":26000,"prior_book_value_yen":42000000,"purpose_ja":"医療関連事業の運営に資する業界動向や事業理解の深化を目的として保有しています。保有の合理性については、毎年取締役会で経済合理性及び定性的保有意義の観点から総合的に保有の妥当性を検証しています。","reciprocal":"有","pct_outstanding":0.005435854099167123,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0018460864944267966,"pct_of_holder_assets":0.0013341077511183873,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":3033444000000,"holder_total_assets_yen":4197562000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"小林製薬株式会社","holder_name_en":"KOBAYASHI PHARMACEUTICAL CO.,LTD.","holder_sec_code":"4967","doc_id":"S100XSXS","period_end":"2025-12-31","holder_table":"reporting","shares":100,"book_value_yen":0,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"当事業年度より、保有目的を純投資目的から純投資目的以外の目的に変更しました。株主総会出席のために保有しております。","reciprocal":"無","pct_outstanding":2.090713115064278e-05,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0,"pct_of_holder_assets":0.0,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":211008000000,"holder_total_assets_yen":275329000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社大阪ソーダ","holder_name_en":"OSAKA SODA CO., LTD.","holder_sec_code":"4046","doc_id":"S100YKCT","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":583000,"prior_book_value_yen":934000000,"purpose_ja":"（保有目的）医療関係事業における取引先であり、同社との関係を維持・強化することにより、当社グループの持続的な成長と中長期的な企業価値の維持・向上に資すると認められるため保有しておりました。","reciprocal":"有","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":128541000000,"holder_total_assets_yen":168741000000,"implausible":false,"reciprocal_held_both_ways":true}],"reclassified":[{"holder_table":"reporting","direction":"to_pure","held_name_raw":"キッセイ薬品工業（株）","held_name_en":"KISSEI PHARMACEUTICAL CO., LTD.","held_sec_code":"4547","match_status":"matched","shares":296485,"book_value_yen":1379000000,"fy_of_change_ja":"2023年3月期","reason_ja":"事業上の関係やシナジー創出等を総合的に検討した結果、純投資目的区分への変更を行っております。先方との売却条件に関する合意に基づき売却を進める方針でおります。","implausible":false},{"holder_table":"reporting","direction":"to_pure","held_name_raw":"カルナバイオサイエンス（株）","held_name_en":"Carna Biosciences, Inc.","held_sec_code":"4572","match_status":"matched","shares":252300,"book_value_yen":96000000,"fy_of_change_ja":"2022年3月期","reason_ja":"事業上の関係やシナジー創出等を総合的に検討した結果、純投資目的区分への変更を行っております。先方との売却条件に関する合意に基づき売却を進める方針でおります。","implausible":false}],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"reporting","note_no":"1","text_ja":"（注）１　「－」は、当該銘柄を保有していないことを示しております。"},{"holder_table":"reporting","note_no":"2","text_ja":"２　貸借対照表計上額が資本金額の100分の１以下でありますが、特定投資株式が60銘柄以下のため全銘柄について記載しております。"},{"holder_table":"reporting","note_no":"3","text_ja":"３　個別銘柄ごとに定量的に捉えられる保有便益と資本コストを比較検証し、リスク等も勘案の上、取引関係（取引金額、取引内容等）や事業上の必要性等の定性情報を加味し、銘柄ごとの具体的な精査を通して、総合的に判断・検証しております。"},{"holder_table":"reporting","note_no":"4","text_ja":"４　（株）Ｔ＆Ｄホールディングスは当社株式を保有しておりませんが、同社子会社である大同生命保険（株）は当社株式を保有しております。"},{"holder_table":"reporting","note_no":"5","text_ja":"５　（株）三菱ＵＦＪフィナンシャル・グループは当社株式を保有しておりませんが、同社子会社である（株）三菱ＵＦＪ銀行は当社株式を保有しております。"},{"holder_table":"reporting","note_no":"6","text_ja":"６　アルフレッサホールディングス（株）は当社株式を保有しておりませんが、同社子会社であるアルフレッサ（株）は当社株式を保有しております。"},{"holder_table":"reporting","note_no":"7","text_ja":"７　（株）いよぎんホールディングスは当社株式を保有しておりませんが、同社子会社である（株）伊予銀行は当社株式を保有しております。"},{"holder_table":"reporting","note_no":"8","text_ja":"８　（株）三井住友フィナンシャルグループは当社株式を保有しておりませんが、同社子会社である（株）三井住友銀行は当社株式を保有しております。"},{"holder_table":"reporting","note_no":"9","text_ja":"９　東海東京フィナンシャル・ホールディングス（株）はみなし保有株式として当社株式を保有しております。"},{"holder_table":"reporting","note_no":"10","text_ja":"10　インフロニア・ホールディングス（株）は当社株式を保有しておりませんが、同社子会社である前田建設工業（株）は当社株式を保有しております。"},{"holder_table":"reporting","note_no":"11","text_ja":"11　ダイト（株）における前事業年度から当事業年度までの株式数の増加は株式分割によるものです。"},{"holder_table":"reporting","note_no":"12","text_ja":"12　（株）バイタルケーエスケー・ホールディングスは当社株式を保有しておりませんが、同社子会社である（株）バイタルネットおよび（株）ケーエスケーは当社株式を保有しております。"},{"holder_table":"reporting","note_no":"13","text_ja":"13　（株）meitoは2025年９月１日付で名糖産業（株）から（株）meitoへ商号変更されております。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"reporting","share_class":"listed","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":7,"sale_proceeds_yen":12968000000,"entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","issues_increased":null,"acquisition_cost_yen":null,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"parent_only","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":77040000000,"listed_yen":76237000000,"unlisted_yen":803000000,"listed_issues":35,"unlisted_issues":13,"equity_yen":850727000000,"equity_basis":"ifrs_consolidated_excl_nci","total_assets_yen":1106515000000,"assets_basis":"ifrs_consolidated","pct_of_equity":9.05578405293355,"pct_of_assets":6.962399967465421,"equity_basis_label":"Consolidated equity attributable to owners of the parent (IFRS)","assets_basis_label":"Consolidated total equity (IFRS)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":76237000000,"issue_count":35,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","book_value_yen":803000000,"issue_count":13,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"}],"scale_history":[{"year":"2022","period_end":"2022-03-31","policy_total_yen":113956000000,"equity_yen":655906000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":17.37383100627224,"pct_of_assets":15.416062975934892},{"year":"2023","period_end":"2023-03-31","policy_total_yen":107795000000,"equity_yen":741869000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":14.530193336020242,"pct_of_assets":12.215602926894498},{"year":"2024","period_end":"2024-03-31","policy_total_yen":101488000000,"equity_yen":792961000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":12.798611785447203,"pct_of_assets":11.107754676753482},{"year":"2025","period_end":"2025-03-31","policy_total_yen":74114000000,"equity_yen":782451000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":9.472030836435763,"pct_of_assets":6.965300372352323},{"year":"2026","period_end":"2026-03-31","policy_total_yen":77040000000,"equity_yen":850727000000,"equity_basis":"ifrs_consolidated_excl_nci","pct_of_equity":9.05578405293355,"pct_of_assets":6.962399967465421}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2019","period_end":"2019-03-31","named_holdings":78,"book_value_yen":146031000000},{"year":"2022","period_end":"2022-03-31","named_holdings":54,"book_value_yen":113153000000},{"year":"2023","period_end":"2023-03-31","named_holdings":52,"book_value_yen":106989000000},{"year":"2024","period_end":"2024-03-31","named_holdings":47,"book_value_yen":100682000000},{"year":"2025","period_end":"2025-03-31","named_holdings":45,"book_value_yen":73312000000},{"year":"2026","period_end":"2026-03-31","named_holdings":40,"book_value_yen":76234000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}